INS and metabolic disease: The results revealed that oral intake of PS-NPs exacerbated metabolic disorders in mice on a HFD, manifesting as suppressed energy expenditure, increased fat mass and liver steatosis, decreased insulin sensitivity, disrupted glucose homeostasis, and reduced cold tolerance compared to the control group.